Alecensa and Hepatic function abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic function abnormal is reported as a side effect among people who take Alecensa (alectinib hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Xgeva, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Hepatic function abnormal when taking Alecensa. It is created by eHealthMe based on reports of 5,131 people who have side effects when taking Alecensa from the FDA, and is updated regularly.

What is Alecensa?

Alecensa has active ingredients of alectinib hydrochloride. eHealthMe is studying from 5,132 Alecensa users. Check the latest studies of Alecensa.

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,478 drugs and 2,010 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

On Dec, 08, 2025

5,131 people reported to have side effects when taking Alecensa.
Among them, 57 people (1.11%) have Hepatic function abnormal.

Could Alecensa cause Hepatic function abnormal?

Among these 57 people:

How long have people been on Alecensa when they have Hepatic function abnormal? *

What is the gender of people who have Hepatic function abnormal when taking Alecensa? *

female: 50.91 %
male: 49.09 %

What is the age of people who have Hepatic function abnormal when taking Alecensa? *

What are other drugs people take besides Alecensa? *

What are other side effects people have besides Hepatic function abnormal? *

Renal Impairment (severely reduced kidney function): 8 people, 14.04%
Constipation: 7 people, 12.28%
Blood Creatine Phosphokinase Increased: 7 people, 12.28%
Weakness: 6 people, 10.53%
Hair Growth Abnormal: 5 people, 8.77%
Anaemia (lack of blood): 5 people, 8.77%
Blood Bilirubin Increased: 5 people, 8.77%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 4 people, 7.02%
Muscle Aches (muscle pain): 4 people, 7.02%
Metastases To Thorax (cancer spreads to thorax): 4 people, 7.02%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 22 people, 38.60%
Lung Cancer - Non-Small Cell (lung cancer): 21 people, 36.84%
Metastases To Central Nervous System (cancer spreads to central nervous system): 8 people, 14.04%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 8 people, 14.04%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 5 people, 8.77%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 4 people, 7.02%
Oedema (fluid collection in tissue): 3 people, 5.26%
Bronchial Carcinoma (lung cancer): 1 person, 1.75%

* Approximation only. Some reports may have incomplete information.

Do you take Alecensa and have Hepatic function abnormal?

- Check whether Hepatic function abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alecensa:

Alecensa (5,132 reports)

Browse all side effects of Alecensa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic function abnormal:

Hepatic function abnormal (1,478 drugs)

Browse all the conditions that are associated with Hepatic function abnormal:

Hepatic function abnormal (2,010 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alectinib hydrochloride (the active ingredients of Alecensa) and Alecensa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.